Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus CCFM1060
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus CCFM1060 is a specific strain of probiotic bacteria being developed as a functional microbial inoculant for both therapeutic and food applications. Research conducted at Jiangnan University's State Key Laboratory of Food Science and Technology in China has indicated its potential in managing metabolic conditions. In diabetic mouse models, the strain has shown efficacy in improving fasting blood glucose, glucose tolerance, and insulin resistance. The proposed mechanism of action involves modulating the gut microbiota, increasing the population of short-chain fatty acid-producing bacteria, strengthening the intestinal barrier, and reducing inflammation through the Nrf2/HO-1 and NF-κB signaling pathways. The strain has been patented for its use in preparing functional foods and medicines for a range of conditions, including type 2 diabetes, high cholesterol, liver inflammation, and fatty liver diseases. Shanghai Helplifes Technology Co., Ltd. is noted as being involved in the commercial production of this strain.
- Other names
- 鼠李糖乳杆菌CCFM1060
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NF-κB
Beyond the preview
Go deeper on Lactobacillus rhamnosus CCFM1060.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus CCFM1060.